Differences in Corneal Parameters Between Affected and Normal Contralateral Eyes in Patients With Hemifacial Spasm Treated With Botulinum Toxin-A

Osaki, Midori Hentona; Osaki, Tammy H.; Hirai, Flávio E.; Campos, Mauro

doi:10.1097/ico.0000000000000688

Cited by 8 publications

(8 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Gunes et al evaluated corneal topographic changes after BTX-A treatment in HFS and BEB patients and reported a signi cant decrease in astigmatism [9]. Similarly, Osaki et al reported that steep keratometry and astigmatism decreased signi cantly at 2 months and 3 months after treatment in HFS patients [34].…”

Section: Discussionmentioning

confidence: 98%

Tear Meniscus, Corneal Topographic and Aberrometric Changes After Botulinum Toxin-A Injection in Patients With Blepharospasm and Hemifacial Spasm

Bilen

Bilen²,

Topçu-Yılmaz

et al. 2021

Preprint

View full text Add to dashboard Cite

Purpose: To investigate the effect of Botulinum neurotoxin-A (BTX-A) treatment on dry eye symptoms, tear meniscus, corneal topography and corneal aberrometry in patients with benign essential blepharospasm (BEB) and hemifacial spasm (HFS).Materials and Methods: This prospective study comprised of 32 eyes from 8 BEB and 24 HFS patients. Tear meniscus height (TMH) and depth (TMD), tear break-up time (TBUT), corneal fluorescein staining score (CFSS), Schirmer I test, ocular surface disease index (OSDI) score, corneal topography [corneal power of flat axis (K1), corneal power of steep axis (K2), mean corneal power (Km), astigmatism and thinnest pachymetry] and anterior corneal aberrometry [spherical aberration (SA), vertical coma (vcoma), horizontal coma (hcoma), higher order root mean square (hRMS) and total RMS] were evaluated before BTX-A treatment and 3 weeks after BTX-A treatment.Results: 3 weeks after BTX-A injection TMH (265.9±116.4 µm vs. 347.1 ± 172.6 µm; p < 0.001) and TMD (178.1 ± 57.7 µm vs. 221.4 ± 90.3 µm; p < 0.001) showed a significant increase. TBUT, CFSS, Schirmer I test values were similar (p > 0.005). OSDI scores decreased significantly from 27.8 ± 26.1 to 18.4 ± 19.8 (p = 0.04). K2 (44.1 ± 1.7 D vs. 43.9 ± 1.7 D p = 0.009), Km (43.7 ± 1.6 D vs. 43.6 ± 1.6 D p = 0.025) and astigmatism (0.9 ± 0.6 D vs. 0.7 ± 0.5 D; p = 0.02) values improved significantly at 3 weeks. Pachymetry and aberrometric values did not change significantly.Conclusion: BTX-A injection increases tear meniscus and decrease symptoms related to dry eye disease in BEB and HFS patients. It decrease astigmatism and keratometry values but it does not cause a significant change in corneal aberrations.

show abstract

Section: Discussionmentioning

confidence: 98%

Tear Meniscus, Corneal Topographic and Aberrometric Changes After Botulinum Toxin-A Injection in Patients With Blepharospasm and Hemifacial Spasm

Bilen

Bilen²,

Topçu-Yılmaz

et al. 2021

Preprint

View full text Add to dashboard Cite

show abstract

“…21 It has been reported that Kmax, k steep and astigmatism are higher on the spasm side in HFS patients. 5,6 Zhang et al showed that front keratometry values were significantly higher in patients with blepharospasm than in normal healthy controls, and the difference was more significant as the spasm severity was greater. 22 In this study, no difference was found between the groups in terms of keratometry and astigmatism values.…”

Section: Discussionmentioning

confidence: 99%

“…5 In HFS patients, corneal astigmatism and keratometry changes were reported after BTX injections. 6…”

Section: Introductionmentioning

confidence: 99%

Evaluating the topographical measurements and tear function status in patients with hemifacial spasm: A comparative fellow eye study

Bilen

2022

European Journal of Ophthalmology

View full text Add to dashboard Cite

Objective To investigate the effect of eyelid spasm on corneal and tear film characteristics in patients with hemifacial spasm (HFS) and compare these data with those of the contralateral eyes of the same patients. Methods This prospective study is comprised of 64 eyes of 32 HFS patients, 32 eyes on the spasm side (Group 1) and 32 contralateral eyes (Group 2). Corneal tomographic analyses were performed; corneal power of flat axis (K1) and steep axis (K2), astigmatism and thinnest pachymetry; anterior, posterior and total corneal aberrometry [spherical aberration (SA), vertical coma (vcoma), horizontal coma (hcoma), total higher order aberration (THOA) and total RMS], and corneal densitometry values were evaluated and compared between groups. Tear meniscus height and depth (TMH, TMD) were measured using anterior segment optic coherence tomography. Tear function tests including TMH and TMD, the Schirmer I test, and tear break-up time (TBUT) were compared between the groups. Results K1, K2, astigmatism and corneal densitometry values were similar between groups (p > 0.05). Thinnest pachymetry values were significantly thinner on the spasm side (p = 0.040). Anterior and total corneal SA and RMS were significantly higher on the spasm side (p = 0.032, p = 0.005; p = 0.015, p = 0.006, respectively). TMH, TMD and TBUT were significantly lower in Group 1 (p = 0.01, p = 0.02 and p = 0.03, respectively). Schirmer I test values were similar between groups (p > 0.05). Conclusion In HFS patients, there are changes in corneal parameters and tear film in the eye on the spasm side compared to unaffected eye.

show abstract

“…Patients were evaluated at baseline and at the 15‐day, 2‐, 3‐ and 4‐month timepoints. Return of the parameters to their pre‐treatment status at the 4‐month timepoint implies that the studied period during which these changes took place represents the BoNT‐A duration [20‐22]. Similarly, further studies that employ the system presented herein could indirectly facilitate the objective assessment of the BoNT‐A duration by evaluating the time period required for the total sum of the power spectrum generated by the upper eyelid movements to return to its baseline levels.…”

Section: Discussionmentioning

confidence: 99%

“…As these conditions may exhibit heterogeneous patterns and a wide range of amplitudes of upper eyelid movements, it is challenging to assess these conditions objectively. Previously employed objective approaches were based on electromyography, eyelid closure force, less accurate systems based on reviewing videotapes or other indirect approaches [17‐24].…”

Section: Introductionmentioning

confidence: 99%

An objective tool to measure the effect of botulinum toxin in blepharospasm and hemifacial spasm

Osaki

Garcia

Osaki

et al. 2020

Euro J of Neurology

View full text Add to dashboard Cite

Background and purpose It is challenging to assess patients with blepharospasm (BSP) and hemifacial spasm (HFS) as these patients exhibit a wide range of amplitudes of eyelid movements. In order to quantify these movements, a mathematical algorithm, i.e. Fast Fourier Transform, can be employed to convert the signal from the time domain to the frequency domain. The result of this quantification represents the energy generated during the eyelid movements. In order to objectively assess the therapeutic effects of botulinum toxin (BoNT) in these patients, we evaluated the energy generated by the upper eyelid during spontaneous eyelid movements before and after treatment. Methods A total of 39 patients with BSP and HFS were evaluated before and 30 days after receiving onabotulinum toxin A injections. A high‐speed camera and micro light‐emitting diodes were used to register the spontaneous eyelid movements. The result of the quantification obtained using Fast Fourier Transform permitted assessment of the activity associated with the eyelid movements. Results We studied 78 eyelids. The total energy generated during spontaneous eyelid movements was significantly reduced after treatment in the patients with BSP (P = 0.0018) and on the affected side in the patients with HFS (P = 0.0058). Conclusions The assessment of the energy generated by the upper eyelid during spontaneous eyelid movements enabled us to measure the therapeutic effects of BoNT in patients with these conditions. The use of this system could enable customized and fine adjustments to BoNT doses based on each patient’s needs.

show abstract

Differences in Corneal Parameters Between Affected and Normal Contralateral Eyes in Patients With Hemifacial Spasm Treated With Botulinum Toxin-A

Abstract: The differences in steep K, and especially in astigmatism values, between eyes tended to reduce during the period of action of BTX-A. At 4 months, when the BTX-A effect is considered to be over or very reduced, a significant difference between eyes for both parameters was noted again.

Cited by 8 publications

References 24 publications

Tear Meniscus, Corneal Topographic and Aberrometric Changes After Botulinum Toxin-A Injection in Patients With Blepharospasm and Hemifacial Spasm

Tear Meniscus, Corneal Topographic and Aberrometric Changes After Botulinum Toxin-A Injection in Patients With Blepharospasm and Hemifacial Spasm

Evaluating the topographical measurements and tear function status in patients with hemifacial spasm: A comparative fellow eye study

An objective tool to measure the effect of botulinum toxin in blepharospasm and hemifacial spasm

Contact Info

Product

Resources

About